Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.59USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
520,538
52-wk High
$6.96
52-wk Low
$1.09

Select another date:

Wed, May 9 2018

BRIEF-Mannkind Q1 Loss Per Share $0.25

* Q1 REVENUE ROSE 15 PERCENT TO $3.4 MILLION Source text for Eikon: Further company coverage:

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-Mannkind Announces $28.0 Million Registered Direct Offering

* MANNKIND ANNOUNCES $28.0 MILLION REGISTERED DIRECT OFFERING

BRIEF-MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group

* MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION

BRIEF-Mannkind Corporation Q4 Loss Per Share $0.28

* ORATION REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage:

Select another date: